Supplemental Materials for JAAD Publication JAAD-D-22-02295, A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of Ivarmacitinib (SHR0302) in Adult Patients with Moderate to Severe Alopecia Areata
Published: 29 March 2023| Version 1 | DOI: 10.17632/9xdmn8wc5f.1
Contributors:
Cheng Zhou, Xiumin Yang, Bin Yang, Guofu Yan, Xiuqin Dong, Yangfeng Ding, Weixin Fan, Linfeng Li, Dingquan Yang, Hong Fang, Chao ji, Hao Cheng, Shoumin Zhang, Aik Han Goh, Rongjun Liu, Xiaoyu Gu, Zaili Weng, Peter Foley, Rod Sinclair, Jianzhong ZhangDescription
These are supplemental data sets to the JAAD publication entitled "A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of Ivarmacitinib (SHR0302) in Adult Patients with Moderate to Severe Alopecia Areata".
Files
Categories
Randomized Clinical Trial, Management of Hair Loss Symptom, Hair Loss, Alopecia Areata, Janus Kinase